| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $267.6M | — | -18.6% |
| Cost of Revenue | $44.3M | — | -6.1% |
| R&D Expense | $13.6M | — | -14.1% |
| SG&A Expense | $46.6M | — | -0.6% |
| Operating Income | $2.9M | — | -91.7% |
| Pre-tax Income | -$3.3M | — | -112.5% |
| Income Tax | $2.6M | — | -69.3% |
| Net Income | $22.3M | — | -8.2% |
| EPS (Basic) | $0.59 | — | +3.5% |
| EPS (Diluted) | $0.59 | — | +5.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $519.7M | -14.4% | +20.6% |
| Accounts Receivable | $397.5M | -40.4% | -23.3% |
| Current Assets | $1.44B | +4.8% | +33.9% |
| Total Assets | $3.39B | -7.3% | -3.5% |
| Current Liabilities | $863.7M | -19.7% | +22.6% |
| Long-term Debt | $867.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $30.0M | — | +45.3% |
| Capital Expenditures | $33.1M | — | +29.3% |
| Investing Cash Flow | -$33.2M | — | +48.8% |
| Financing Cash Flow | -$53.5M | — | -52.8% |
| Free Cash Flow | -$3.2M | — | +36.6% |
| +0.3% |
| Total Liabilities | $1.67B | -12.4% | -1.3% |
| Stockholders' Equity | $1.72B | -1.8% | -5.5% |